METHODS: The present study describes clinical outcomes, clinical response, mortality, overall survival, and progression-free survival to two years in a group of patients with germinal malignant tumors, seminoma versus non-seminomatous with evidence of progression of the disease at first, second, or third conventional chemotherapy regimens, and who received high dose chemotherapy and bone marrow transplantation at the National Cancer Institute between 2010 and 2021.
RESULTS: A retrospective observational study of case series showed that 57% of patients in third-line therapy received high-dose chemotherapy and bone marrow transplantation, with progression disease median time from diagnosis more than two years. Patients in the post-graft period presented infectious complications (71%). The most common were febrile neutropenia (29%) with a mortality rate of 71% (n=5), progression-free survival of 2.3 months, and overall survival of 7.4 months.
CONCLUSIONS: These results show that in this group of patients, regimens with high-dose chemotherapy associated with bone marrow transplants, have a worse prognosis compared to other cohorts of patients, and may not be the best candidates for this rescue therapy.
方法:本研究描述了临床结果,临床反应,死亡率,总生存率,一组生发恶性肿瘤患者的无进展生存期为两年,精原细胞瘤与非精原细胞瘤,首先有疾病进展的证据,第二,或第三种常规化疗方案,并在2010年至2021年期间在美国国家癌症研究所接受了高剂量化疗和骨髓移植。
结果:一项病例系列的回顾性观察性研究表明,57%的三线治疗患者接受了大剂量化疗和骨髓移植,从诊断开始的中位疾病进展时间超过两年。移植后患者出现感染性并发症(71%)。最常见的是发热性中性粒细胞减少症(29%),死亡率为71%(n=5)。无进展生存期2.3个月,总生存期为7.4个月。
结论:这些结果表明,在这组患者中,与骨髓移植相关的大剂量化疗方案,与其他患者相比,预后较差,并且可能不是这种抢救疗法的最佳候选人。